title: Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer.
abstract: OBJECTIVE
  Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.
  
  
  METHODS
  Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.
  
  
  RESULTS
  Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.
  
  
  CONCLUSIONS
  In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.
authors.affiliation: Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark, Iben.Kumler@regionh.dk.
authors.forename: Iben
authors.initials: I
authors.lastname: Kümler
authors.forename: Vibeke Kirk
authors.initials: VK
authors.lastname: Parner
authors.forename: Malgorzata K
authors.initials: MK
authors.lastname: Tuxen
authors.forename: Bjørn
authors.initials: B
authors.lastname: Skjoldbye
authors.forename: Magnus
authors.initials: M
authors.lastname: Bergenfeldt
authors.forename: Knud Mejer
authors.initials: KM
authors.lastname: Nelausen
authors.forename: Dorte Lisbet
authors.initials: DL
authors.lastname: Nielsen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000473:pathology*; D017115:Catheter Ablation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D016896:Treatment Outcome